Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Teva Pharmaceutical Industries (TEVA) and increased the price target from $19 to $20.
May 13, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's reiteration of an Overweight rating and increase in price target for TEVA from $19 to $20 suggests a positive outlook on the stock's future performance.
The analyst's decision to raise the price target reflects a strong conviction in TEVA's potential for growth. Such endorsements often lead to increased investor confidence and can positively impact the stock's short-term price movement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100